Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib in Newly Diagnosed Peripheral T Cell Lymphoma (GOLDEN Study)
NCT06630091Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of golidocitinib in peripheral T-cell lymphoma (PTCL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Progression-Free Survival at 2 years and Safety and Adverse Events at 1 year. Started Feb 2025; status: recruiting.
02
Drugs
golidocitinib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT06630091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06630091.